News Briefs: HHS Unveils Draft Guidance on Using March-In Rights

On Dec. 8, the U.S. Department of Commerce’s National Institute of Standards and Technology and HHS unveiled draft guidance (88 Fed. Reg. 85593) on framework for exercising march-in rights on taxpayer-funded drugs and other products. The framework “specifies that price can be a factor in considering whether a drug is accessible to the public,” the administration said. That was one of other “new actions to promote competition in health care and support lowering prescription drug costs for American families.” Comments must be received by 5 p.m. Eastern on Feb. 6.

Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 9

News Briefs: Ventegra Will Prefer Yuflyma

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
October 12

News Briefs: Boehringer Ingelheim Launched Unbranded Interchangeable Humira Biosimilar

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
September 14

News Briefs: Groups Sue HHS Over Lost Coverage of Certain Medicare Part B Drugs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today